Paolo Tarantino

List of Publications by Year
in descending order

51	1,716	394421	330143
papers	citations	19 h-index	37 g-index

51	51	51	1630
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology, 2020, 38, 1951-1962.	1.6	353
2	Antibodyâ€“drug conjugates: Smart chemotherapy delivery across tumor histologies. Ca-A Cancer Journal for Clinicians, 2022, 72, 165-182.	329.8	132
3	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Advances in Experimental Medicine and Biology, 2019, 1168, 9-30.	1.6	114
4	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Critical Reviews in Oncology/Hematology, 2019, 133, 171-182.	4.4	93
5	Evolution of low HER2 expression between early and advanced-stage breast cancer. European Journal of Cancer, 2022, 163, 35-43.	2.8	88
6	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Npj Breast Cancer, 2022, 8, 23.	5.2	67
7	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. JAMA Oncology, 2021, 7, 1873.	7.1	66
8	The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 221, 746-754.	1.7	60
9	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treatment Reviews, 2022, 106, 102395.	7.7	60
10	SARS-CoV-2 vaccines for cancer patients: a call to action. European Journal of Cancer, 2021, 148, 316-327.	2.8	55
11	Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2021, 159, 103223.	4.4	52
12	Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World Journal of Gastroenterology, 2017, 23, 906.	3.3	51
13	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncology, 0, , .	7.1	51
14	Bystander effect of antibodyâ€“drug conjugates: fact or fiction?. Current Oncology Reports, 2022, 24, 809-817.	4.0	35
15	Cardiovascular risk markers in patients with primary aldosteronism: A systematic review and meta-analysis of literature studies. International Journal of Cardiology, 2016, 208, 46-55.	1.7	30
16	Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: A feasibility study. European Journal of Surgical Oncology, 2018, 44, 1603-1609.	1.0	28
17	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews, 2021, 99, 102253.	7.7	26
18	Viral hepatitis and anti-phospholipid antibodies positivity: A systematic review and meta-analysis. Digestive and Liver Disease, 2015, 47, 478-487.	0.9	25

#	Article	IF	Citations
19	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer, 2021, 154, 151-160.	2.0	25
20	Autoimmune Liver Diseases and Antiphospholipid Antibodies Positivity: a Meta-analysis of Literature Studies. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 25-34.	0.9	24
21	Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opinion on Biological Therapy, 2020, 20, 1009-1024.	3.1	23
22	Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy, 2021, 21, 127-133.	3.1	21
23	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. Cancer Treatment Reviews, 2021, 97, 102205.	7.7	21
24	Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer. JAMA Oncology, 2022, 8, 629.	7.1	18
25	Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals, 2021, 14, 884.	3.8	17
26	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188487.	7.4	16
27	Defining the immunogram of breast cancer: a focus on clinical trials. Expert Opinion on Biological Therapy, 2019, 19, 383-385.	3.1	14
28	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treatment Reviews, 2021, 94, 102169.	7.7	14
29	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13
30	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. European Journal of Cancer, 2020, 139, 92-98.	2.8	12
31	Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)â€“related disease pandemic. European Journal of Cancer, 2020, 132, 8-10.	2.8	12
32	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Annals of Oncology, 2022, 33, 234-238.	1.2	11
33	Harmonizing PD-L1 testing in metastatic triple negative breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 345-348.	3.1	10
34	Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers, 2022, 14, 3193.	3.7	9
35	Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opinion on Investigational Drugs, 2021, , 1-15.	4.1	8
36	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers, 2021, 13, 5829.	3.7	8

#	Article	IF	Citations
37	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
38	Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancerâ€"Should We Go â€œAll Inâ€?â€"Reply. JAMA Oncology, 2022, 8, 1221.	7.1	8
39	Mastering the Use of Novel Anti-HER2 Treatment Options. JCO Oncology Practice, 2021, 17, 605-606.	2.9	6
40	Anthracyclines for Human Epidermal Growth Factor Receptor 2â€"Positive Breast Cancer: Are We Ready to Let Them Go?. Journal of Clinical Oncology, 2021, 39, 3541-3545.	1.6	6
41	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 141-153.	2.4	5
42	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Nonâ€"Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	2.9	4
43	Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews, 2021, 92, 102133.	7.7	4
44	Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. , 2019, 2, 43-52.		4
45	New anti-HER2 agents for brain metastasis: histology-agnostic weapons?. Breast Cancer Research and Treatment, 2021, 185, 879-881.	2.5	3
46	Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. Breast Cancer Research and Treatment, 2021, 186, 885-886.	2.5	3
47	Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. Expert Opinion on Investigational Drugs, 2022, 31, 855-874.	4.1	2
48	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.8	1
49	RADIOFREQUENCY ABLATION FOR LIVER METASTASES IN THE TREATMENT OF ADVANCED BREAST CANCER. Breast, 2019, 48, S74.	2.2	0
50	Percutaneous electrochemotherapy of malignant main portal veins thrombosis: a prospective case series.. Journal of Clinical Oncology, 2016, 34, e15586-e15586.	1.6	0
51	Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. Journal of Clinical Oncology, 2022, 40, 3063-3063.	1.6	0